Recursion's stock has been consistently rated as "Hold" by this analyst due to skepticism about its AI-driven drug discovery approach and its financial instability. The company's IPO raised over $500 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback